Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02608619 · ClinicalTrials.gov registry record
Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 3
- Enrollment target
NCT02608619: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02608619 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02608619 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 3 participants
- Enrollment target
Study Summary
The main purpose of this study is to discover how 18F-cholineFCH distributes in the body, and see if it can distinguish active histiocytes (tumor) from inflammatory (non- tumor) cells. This tracer has the potential to give the investigators' team more information when trying to identify the tumor cells that are most important to collect with biopsy. In addition, the study will measure levels of 18F-cholineFCH in the biopsy tissue.
Interventions
- PROCEDURE biopsy
- DEVICE FDG-PET
- RADIATION F-choline PET Scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-11 |
| Est. Completion | 2018-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02608619
The ClinicalTrials.gov registry entry for NCT02608619 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which biopsy is the first listed.
NCT02608619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02608619 about?
NCT02608619 is a clinical study titled "Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement". The main purpose of this study is to discover how 18F-cholineFCH distributes in the body, and see if it can distinguish active histiocytes (tumor) from inflammatory (non- tumor) cells. This tracer has the potential to give the investigators' team more information when trying to identify the tumor ce...
What is the current status of trial NCT02608619?
This trial is currently completed. The enrollment target is 3 participants. The study started on 2015-11. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02608619?
The interventions under investigation include: biopsy (PROCEDURE), FDG-PET (DEVICE), F-choline PET Scan (RADIATION).
Who is sponsoring clinical trial NCT02608619?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.